Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neflamapimod - CervoMed

Next Previous
Drug Profile

Neflamapimod - CervoMed

Alternative Names: VX-745

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer CervoMed; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Antidementias; Nootropics; Pyridazines; Small molecules; Sulfides
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Huntington's disease; Lewy body disease
  • Phase I Frontotemporal dementia; Stroke
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 10 Apr 2024 CervoMed plans a phase III trial for Lewy body disease in the mid of 2025
  • 12 Feb 2024 Phase-II clinical trials in Lewy body disease in United Kingdom (PO) prior to February 2024 ,
  • 12 Feb 2024 Efficacy data from the phase-IIa AscenD-LB trial in Lewy body disease released by CervoMed
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top